Évaluation de l’imatinib dans la prise en charge de la leucémie myéloïde chronique au Gabon À propos de dix-sept cas Volume 26, numéro 2, Avril-Mai- Juin. REVUE MEDICALE DE LIEGE. Cliquer ICI pour déclencher le téléchargement de l’article. COMMENT JE TRAITE LA LEUCEMIE MYELOIDE CHRONIQUE. Résumé La leucémie myéloïde chronique (LMC) est un modèle de cancérogenèse. Son pronostic a été exceptionnellement amélioré grâce.
|Published (Last):||10 August 2014|
|PDF File Size:||12.68 Mb|
|ePub File Size:||13.65 Mb|
|Price:||Free* [*Free Regsitration Required]|
Personal information regarding our website’s visitors, including their identity, is confidential.
Leucémie myéloïde chronique (LMC)
myeloiide Contact Help Who are we? Journal page Archives Contents list. Finally, the immune system undoubtedly plays a crucial function in the control of residual leukemic cells; this role should be specified in the future. Top of the page – Article Outline. Indian J Hematol Blood Transfus. As per the Law relating to information storage and personal integrity, you have the right to oppose art 26 of that lawaccess art 34 of that law and rectify art 36 of that law your personal data.
If you are a subscriber, please sign in ‘My Account’ at the top right of the screen.
Chronic myeloid leukemia advances in biology and new approaches to treatment. Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: Clinical and pronognostic features of Nigerians with chronic myeloid leukemia. The persistence of TKI-refractory leukemic stem cells could explain this result. East Afr Med J.
Frequency of BCR-ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction.
Molecular biology of bcr-abl1-positive CML. New technologies chronoque PCR, high-throughput sequencing or NGS were developed to improve the performances of existing methods.
S Af Med J. Tyrosine kinase inhibitor TKI therapy imatinib, dasatinib, nilotinib, bosutinib, ponatinib has led to improved overall and disease-free survival of patients.
RMLG – ACCES A L’ARTICLE :COMMENT JE TRAITE LA LEUCEMIE MYELOIDE CHRONIQUE (LMC).
International recommendations leucemue the management of CML and treatment adjustments. Access to the full text of this article requires a subscription. A retrospective study of leukemia epidemiology in Northern Tunisia.
For the remaining half of patients, the causes leading to the molecular relapse deserve to be further analyzed.
N Engl J Med. Outline Masquer le plan. Access to the PDF text. New strategies to eradicate these residual cells by targeting the hematopoietic niche or directly the leukemic stem cells are being developed. Les inhibiteurs des kinases.
Clinical trials chronkque validated TKI discontinuation strategies in patients with sustained deep molecular response. Hematologic and cytogenetic response to Imatinib mesylate in chronic myelogenous leukemia. You can move this window chonique clicking on the headline.
Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted. Regional chroniqu in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries.
Chronic myeloid leukaemia in South African blacks.
Médecine et Santé Tropicales
Acellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. If you want to subscribe to this journal, see our rates You can purchase this item in Pay Per View: Access to the text HTML. Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi.
The Glivec international patient assistance programme: Chronic myeloid leukaemia in central Africans. An experience from eastern India. The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.